News
FEIBA in Real Clinical Practice – Fresh Data from the Observational Study FEIBA GO
FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and high-titer inhibitors (high responders), who were receiving aPCC in routine clinical practice. The study, whose results were recently published, was conducted at 25 centers in 11 countries.
Untreated Bleeding in Hemophilia A – An Underestimated Problem? To What Extent?
How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a…
Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience
The authors of a recent study, summarizing real-world experience from the US, focused on the…
Minimally Invasive Treatment of Pilonidal Sinus: Laser and Negative Pressure Therapy as a Gentle and Effective Modality
The increasing incidence of pilonidal sinus contributes to the development of new treatment…
Reduction of Enthesitis in Patients with Psoriatic Arthritis Taking Tofacitinib
Inflammation in the area where a tendon, ligament, or joint capsule attaches to the bone occurs in…
How do body weight and metabolic parameters change in patients first hospitalized for psychosis?
The most common cause of death in patients with schizophrenia is cardiovascular disease, which is…
Prof. Hana Rosolová: According to recent studies, caution is needed with beta-blockers only in severe cases of asthma and COPD
Beta-blockers (BB) are among the most widely used drug groups in cardiology. While their position…
Reduction of Inflammation in Vertebral Bodies and Posterolateral Structures of the Spine in Patients with Ankylosing Spondylitis Treated with Tofacitinib
A post hoc analysis of a phase II study with tofacitinib in patients with active ankylosing…
How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?
What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the…
Romiplostim brings benefit also to patients with ITP lasting less than 1 year
What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP…